Meropenem Kabi

Meropenem, the active ingredient in Meropenem Kabi, is a carbapenem antibiotic presented as an injectable solution for intravenous use. It is employed to treat serious bacterial infections in hospitalized patients, including intra‑abdominal, urinary, pulmonary, central nervous system, and septic conditions and other life‑threatening infections.

GNH USA supplies Meropenem Kabi as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory documentation for import globally.

Meropenem is a broad‑spectrum carbapenem antibiotic used for serious bacterial infections affecting various organ systems.

Complicated intra‑abdominal infections: achieves rapid bacterial eradication to resolve intra‑abdominal sepsis. Complicated urinary tract infections: provides effective coverage against resistant uropathogens, facilitating cure of pyelonephritis. Hospital‑acquired pneumonia: delivers bactericidal activity to clear pulmonary infection and improve respiratory function. Ventilator‑associated pneumonia: penetrates lung tissue to eliminate pathogens causing ventilator‑related infection. Meningitis: crosses the blood‑brain barrier to eradicate bacterial meningitis agents. Severe sepsis and septic shock: offers broad‑spectrum coverage essential for hemodynamic stabilization.

Meropenem may be associated with a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Nausea: mild to moderate feeling of sickness, often transient. - Diarrhea: loose stools that may range from mild to severe. - Headache: occasional throbbing pain, usually resolves without intervention. - Elevated liver enzymes: transient increase in hepatic transaminases. - Vomiting: occasional emesis that may accompany nausea. - Injection site pain: discomfort or erythema at the infusion site.

Serious or Rare Side Effects: - Seizures: risk increases with high doses or renal impairment. - Severe allergic reactions: including anaphylaxis, rash, and angioedema. - Clostridioides difficile colitis: may cause severe diarrhea and colitis. - Thrombocytopenia: reduced platelet count leading to bleeding tendency.

When using Meropenem, clinicians should consider several precautionary measures to ensure safe and effective therapy. - Renal function assessment: adjust dose in patients with impaired kidney function. - Hypersensitivity screening: avoid use in individuals with known carbapenem or β‑lactam allergy. - Concomitant nephrotoxic drugs: monitor for additive renal toxicity when combined with other nephrotoxic agents. - Electrolyte monitoring: watch for potential hypokalemia during prolonged therapy. - Superinfection vigilance: be alert for secondary infections such as fungal overgrowth or C. difficile. - Store at 2‑8 °C: keep refrigerated, protect from light, do not freeze or shake.

Meropenem may interact with other medicines, influencing its efficacy or safety profile.

Major Interactions (Avoid): - Valproic acid: concomitant use can reduce valproate levels, risking seizure breakthrough. - Probenecid: may decrease renal clearance of meropenem, increasing toxicity risk. - High‑dose aminoglycosides: combined nephrotoxicity may be enhanced.

Moderate Interactions (Monitor Closely): - Loop diuretics: monitor renal function and electrolytes due to additive nephrotoxic potential. - Anticoagulants (e.g., warfarin): may require INR monitoring as infection resolution can alter coagulation. - Oral contraceptives: bacterial eradication may affect gut flora, potentially reducing contraceptive efficacy. - Phenytoin: may increase meropenem clearance, potentially lowering phenytoin concentrations.